Dr Daniel Murphy

  • Reader (Beatson Institute for Cancer Research)

Grants

Grants and Awards listed are those received whilst working with the University of Glasgow.

  • Pre-clinical in vivo evaluation of immuno-modulatory therapy in MPM
    British Lung Foundation (BLF)
    2019 - 2022
     
  • Pre-clinical evaluation of pan-ERBB inhibition to treat KRAS mutant NSCLC
    British Lung Foundation
    2017 - 2020
     
  • NuSiCC
    European Commission
    2016 - 2018
     
  • SERPLUC: Suppression of Enzymes Required for Progression of Lung Cancer
    European Commission
    2013 - 2017
     
  • Metabolic vulnerabilities induced by Myc
    Cancer Research UK
    2012 - 2013
     

Research datasets

Publications

List by: Type | Date

Jump to: 2019 | 2018 | 2017 | 2015 | 2014 | 2013 | 2012 | 2009 | 2008 | 2005 | 2004 | 2001 | 1999
Number of items: 33.

2019

Neidler, S. et al. (2019) Identification of a clinically relevant signature for early progression in KRAS-driven lung adenocarcinoma. Cancers, 11(5), 600. (doi:10.3390/cancers11050600) (PMID:31032816)

Scopelliti, A., Bauer, C. , Yu, Y., Zhang, T., Kruspig, B., Murphy, D. J. , Vidal, M., Maddocks, O. D.K. and Cordero, J. B. (2019) A neuronal relay mediates a nutrient responsive gut/fat body axis regulating energy homeostasis in adult Drosophila. Cell Metabolism, 29(2), 269-284.e10. (doi:10.1016/j.cmet.2018.09.021) (PMID:30344016) (PMCID:PMC6370946)

2018

Muthalagu, N. and Murphy, D. J. (2018) Is oxidative stress MYC’s Achilles heel? Cell Death and Differentiation, 25(7), pp. 1189-1190. (doi:10.1038/s41418-018-0117-4) (PMID:29844569)

Kruspig, B. et al. (2018) The ERBB network facilitates KRAS-driven lung tumorigenesis. Science Translational Medicine, 10(446), eaao2565. (doi:10.1126/scitranslmed.aao2565) (PMID:29925636)

Port, J. et al. (2018) Colorectal tumors require NUAK1 for protection from oxidative stress. Cancer Discovery, 8(5), pp. 632-647. (doi:10.1158/2159-8290.CD-17-0533) (PMID:29500295)

Monteverde, T., Tait-Mulder, J., Hedley, A.,, Knight, J.R., Sansom, O.J. and Murphy, D.J. (2018) Calcium signalling links MYC to NUAK1. Oncogene, 37(8), pp. 982-992. (doi:10.1038/onc.2017.394) (PMID:29106388)

Blyth, K. G. and Murphy, D. J. (2018) Progress and challenges in Mesothelioma: from bench to bedside. Respiratory Medicine, 134, pp. 31-41. (doi:10.1016/j.rmed.2017.11.015)

2017

Walton, J. B. et al. (2017) CRISPR/Cas9-derived models of ovarian high grade serous carcinoma targeting Brca1, Pten and Nf1, and correlation with platinum sensitivity. Scientific Reports, 7, 16827. (doi:10.1038/s41598-017-17119-1) (PMID:29203787) (PMCID:PMC5715106)

Farrell, A. S. et al. (2017) MYC regulates ductal-neuroendocrine lineage plasticity in pancreatic ductal adenocarcinoma associated with poor outcome and chemoresistance. Nature Communications, 8(1), 1728. (doi:10.1038/s41467-017-01967-6) (PMID:29170413) (PMCID:PMC5701042)

Port, J. and Murphy, D. J. (2017) Mesothelioma: identical routes to malignancy from asbestos and carbon nanotubes. Current Biology, 27(21), R1173-R1176. (doi:10.1016/j.cub.2017.07.026) (PMID:29112873)

Murphy, D. J. and Blyth, K. G. (2017) Predicting lung cancer recurrence from circulating tumour DNA. Commentary on 'Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution'. Cell Death and Differentiation, 24(9), pp. 1473-1474. (doi:10.1038/cdd.2017.97) (PMID:28622291)

Hock, A. K. et al. (2017) Development of an inducible mouse model of iRFP713 to track recombinase activity and tumour development in vivo. Scientific Reports, 7, 1837. (doi:10.1038/s41598-017-01741-0) (PMID:28500323) (PMCID:PMC5431786)

Sarosiek, K. A. et al. (2017) Developmental regulation of mitochondrial apoptosis by c-Myc governs age- and tissue-specific sensitivity to cancer therapeutics. Cancer Cell, 31(1), pp. 142-156. (doi:10.1016/j.ccell.2016.11.011) (PMID:28017613)

Iltzsche, F. et al. (2017) An important role for Myb-MuvB and its target gene KIF23 in a mouse model of lung adenocarcinoma. Oncogene, 36(1), pp. 110-121. (doi:10.1038/onc.2016.181) (PMID:27212033)

2015

Bott, A. J. et al. (2015) Oncogenic Myc induces expression of glutamine synthetase through promoter demethylation. Cell Metabolism, 22(6), pp. 1068-1077. (doi:10.1016/j.cmet.2015.09.025) (PMID:26603296)

Monteverde, T., Muthalagu, N., Port, J. and Murphy, D. (2015) Evidence of cancer-promoting roles for AMPK and related kinases. FEBS Journal, 282(24), pp. 4658-4671. (doi:10.1111/febs.13534) (PMID:26426570)

Ichim, G. et al. (2015) Limited mitochondrial permeabilization causes DNA damage and genomic instability in the absence of cell death. Molecular Cell, 57(5), pp. 860-872. (doi:10.1016/j.molcel.2015.01.018) (PMID:25702873) (PMCID:PMC4352766)

Leikam, C. et al. (2015) In vitro evidence for senescent multinucleated melanocytes as a source for tumor-initiating cells. Cell Death and Disease, 6(4), e1711. (doi:10.1038/cddis.2015.71) (PMID:25837487)

Murphy, D. J. and Muthalagu, N. (2015) BIM's up first. Molecular and Cellular Oncology, 2(2), e975083. (doi:10.4161/23723556.2014.975083)

2014

Kamphorst, J. J. and Murphy, D. J. (2014) The 2014 Beatson International Cancer Conference: Powering the Cancer Machine. Cancer and Metabolism, 2(1), 25. (doi:10.1186/2049-3002-2-25)

Muthalagu, N., Junttila, M. R., Wiese, K. E., Wolf, E., Morton, J., Bauer, B., Evan, G. I., Eilers, M. and Murphy, D. J. (2014) BIM is the primary mediator of MYC-induced apoptosis in multiple solid tissues. Cell Reports, 8(5), pp. 1347-1353. (doi:10.1016/j.celrep.2014.07.057)

2013

Bommert, K.S. et al. (2013) The feed-forward loop between YB-1 and MYC is essential for multiple myeloma cell survival. Leukemia, 27(2), pp. 441-450. (doi:10.1038/leu.2012.185)

2012

Liu, L. et al. (2012) Deregulated MYC expression induces dependence upon AMPK-related kinase 5. Nature, 483(7391), pp. 608-612. (doi:10.1038/nature10927)

2009

Khanna, A. et al. (2009) MYC-dependent regulation and prognostic role of cip2a in gastric cancer. Journal of the National Cancer Institute, 101(11), pp. 793-805. (doi:10.1093/jnci/djp103)

2008

Murphy, D.J. , Junttila, M.R., Pouyet, L., Karnezis, A., Shchors, K., Bui, D.A., Brown-Swigart, L., Johnson, L. and Evan, G.I. (2008) Distinct thresholds govern Myc's biological output In vivo. Cancer Cell, 14(6), pp. 447-457. (doi:10.1016/j.ccr.2008.10.018)

Soucek, L., Whitfield, J., Martins, C.P., Finch, A.J., Murphy, D.J. , Sodir, N.M., Karnezis, A.N., Swigart, L.B., Nasi, S. and Evan, G.I. (2008) Modelling Myc inhibition as a cancer therapy. Nature, 455(7213), pp. 679-683. (doi:10.1038/nature07260)

Golipour, A., Myers, D., Seagroves, T., Murphy, D. , Evan, G.I., Donoghue, D.J., Moorehead, R.A. and Porter, L.A. (2008) The Spy1/RINGO family represents a novel mechanism regulating mammary growth and tumorigenesis. Cancer Research, 68(10), pp. 3591-3600. (doi:10.1158/0008-5472.CAN-07-6453)

Rao, M. et al. (2008) Inhibition of cyclin D1 gene transcription by Brg-1. Cell Cycle, 7(5), pp. 647-655. (doi:10.4161/cc.7.5.5446)

2005

Evan, G.I., Christophorou, M., Lawlor, E.A., Ringshausen, I., Prescott, J., Dansen, T., Finch, A., Martins, C. and Murphy, D. (2005) Oncogene-dependent tumor suppression: using the dark side of the force for cancer therapy. Cold Spring Harbor Symposia on Quantitative Biology, 70, pp. 263-273. (doi:10.1101/sqb.2005.70.054)

2004

Flores, I., Murphy, D.J. , Swigart, L.B., Knies, U. and Evan, G.I. (2004) Defining the temporal requirements for Myc in the progression and maintenance of skin neoplasia. Oncogene, 23(35), pp. 5923-5930. (doi:10.1038/sj.onc.1207796)

Murphy, D.J. , Swigart, L.B., Israel, M.A. and Evan, G.I. (2004) Id2 is dispensable for myc-induced epidermal neoplasia. Molecular and Cellular Biology, 24(5), pp. 2083-2090. (doi:10.1128/MCB.24.5.2083-2090.2004)

2001

Deeble, P.D., Murphy, D.J. , Parsons, S.J. and Cox, M.E. (2001) Interleukin-6- and cyclic amp-mediated signaling potentiates neuroendocrine differentiation of lncap prostate tumor cells. Molecular and Cellular Biology, 21(24), pp. 8471-8482. (doi:10.1128/MCB.21.24.8471-8482.2001)

1999

Murphy, D.J. , Hardy, S. and Engel, D.A. (1999) Human SWI-SNF component BRG1 represses transcription of the c-fos gene. Molecular and Cellular Biology, 19(4), pp. 2724-33.

This list was generated on Sun Jul 21 11:18:57 2019 BST.
Jump to: Articles
Number of items: 33.

Articles

Neidler, S. et al. (2019) Identification of a clinically relevant signature for early progression in KRAS-driven lung adenocarcinoma. Cancers, 11(5), 600. (doi:10.3390/cancers11050600) (PMID:31032816)

Scopelliti, A., Bauer, C. , Yu, Y., Zhang, T., Kruspig, B., Murphy, D. J. , Vidal, M., Maddocks, O. D.K. and Cordero, J. B. (2019) A neuronal relay mediates a nutrient responsive gut/fat body axis regulating energy homeostasis in adult Drosophila. Cell Metabolism, 29(2), 269-284.e10. (doi:10.1016/j.cmet.2018.09.021) (PMID:30344016) (PMCID:PMC6370946)

Muthalagu, N. and Murphy, D. J. (2018) Is oxidative stress MYC’s Achilles heel? Cell Death and Differentiation, 25(7), pp. 1189-1190. (doi:10.1038/s41418-018-0117-4) (PMID:29844569)

Kruspig, B. et al. (2018) The ERBB network facilitates KRAS-driven lung tumorigenesis. Science Translational Medicine, 10(446), eaao2565. (doi:10.1126/scitranslmed.aao2565) (PMID:29925636)

Port, J. et al. (2018) Colorectal tumors require NUAK1 for protection from oxidative stress. Cancer Discovery, 8(5), pp. 632-647. (doi:10.1158/2159-8290.CD-17-0533) (PMID:29500295)

Monteverde, T., Tait-Mulder, J., Hedley, A.,, Knight, J.R., Sansom, O.J. and Murphy, D.J. (2018) Calcium signalling links MYC to NUAK1. Oncogene, 37(8), pp. 982-992. (doi:10.1038/onc.2017.394) (PMID:29106388)

Blyth, K. G. and Murphy, D. J. (2018) Progress and challenges in Mesothelioma: from bench to bedside. Respiratory Medicine, 134, pp. 31-41. (doi:10.1016/j.rmed.2017.11.015)

Walton, J. B. et al. (2017) CRISPR/Cas9-derived models of ovarian high grade serous carcinoma targeting Brca1, Pten and Nf1, and correlation with platinum sensitivity. Scientific Reports, 7, 16827. (doi:10.1038/s41598-017-17119-1) (PMID:29203787) (PMCID:PMC5715106)

Farrell, A. S. et al. (2017) MYC regulates ductal-neuroendocrine lineage plasticity in pancreatic ductal adenocarcinoma associated with poor outcome and chemoresistance. Nature Communications, 8(1), 1728. (doi:10.1038/s41467-017-01967-6) (PMID:29170413) (PMCID:PMC5701042)

Port, J. and Murphy, D. J. (2017) Mesothelioma: identical routes to malignancy from asbestos and carbon nanotubes. Current Biology, 27(21), R1173-R1176. (doi:10.1016/j.cub.2017.07.026) (PMID:29112873)

Murphy, D. J. and Blyth, K. G. (2017) Predicting lung cancer recurrence from circulating tumour DNA. Commentary on 'Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution'. Cell Death and Differentiation, 24(9), pp. 1473-1474. (doi:10.1038/cdd.2017.97) (PMID:28622291)

Hock, A. K. et al. (2017) Development of an inducible mouse model of iRFP713 to track recombinase activity and tumour development in vivo. Scientific Reports, 7, 1837. (doi:10.1038/s41598-017-01741-0) (PMID:28500323) (PMCID:PMC5431786)

Sarosiek, K. A. et al. (2017) Developmental regulation of mitochondrial apoptosis by c-Myc governs age- and tissue-specific sensitivity to cancer therapeutics. Cancer Cell, 31(1), pp. 142-156. (doi:10.1016/j.ccell.2016.11.011) (PMID:28017613)

Iltzsche, F. et al. (2017) An important role for Myb-MuvB and its target gene KIF23 in a mouse model of lung adenocarcinoma. Oncogene, 36(1), pp. 110-121. (doi:10.1038/onc.2016.181) (PMID:27212033)

Bott, A. J. et al. (2015) Oncogenic Myc induces expression of glutamine synthetase through promoter demethylation. Cell Metabolism, 22(6), pp. 1068-1077. (doi:10.1016/j.cmet.2015.09.025) (PMID:26603296)

Monteverde, T., Muthalagu, N., Port, J. and Murphy, D. (2015) Evidence of cancer-promoting roles for AMPK and related kinases. FEBS Journal, 282(24), pp. 4658-4671. (doi:10.1111/febs.13534) (PMID:26426570)

Ichim, G. et al. (2015) Limited mitochondrial permeabilization causes DNA damage and genomic instability in the absence of cell death. Molecular Cell, 57(5), pp. 860-872. (doi:10.1016/j.molcel.2015.01.018) (PMID:25702873) (PMCID:PMC4352766)

Leikam, C. et al. (2015) In vitro evidence for senescent multinucleated melanocytes as a source for tumor-initiating cells. Cell Death and Disease, 6(4), e1711. (doi:10.1038/cddis.2015.71) (PMID:25837487)

Murphy, D. J. and Muthalagu, N. (2015) BIM's up first. Molecular and Cellular Oncology, 2(2), e975083. (doi:10.4161/23723556.2014.975083)

Kamphorst, J. J. and Murphy, D. J. (2014) The 2014 Beatson International Cancer Conference: Powering the Cancer Machine. Cancer and Metabolism, 2(1), 25. (doi:10.1186/2049-3002-2-25)

Muthalagu, N., Junttila, M. R., Wiese, K. E., Wolf, E., Morton, J., Bauer, B., Evan, G. I., Eilers, M. and Murphy, D. J. (2014) BIM is the primary mediator of MYC-induced apoptosis in multiple solid tissues. Cell Reports, 8(5), pp. 1347-1353. (doi:10.1016/j.celrep.2014.07.057)

Bommert, K.S. et al. (2013) The feed-forward loop between YB-1 and MYC is essential for multiple myeloma cell survival. Leukemia, 27(2), pp. 441-450. (doi:10.1038/leu.2012.185)

Liu, L. et al. (2012) Deregulated MYC expression induces dependence upon AMPK-related kinase 5. Nature, 483(7391), pp. 608-612. (doi:10.1038/nature10927)

Khanna, A. et al. (2009) MYC-dependent regulation and prognostic role of cip2a in gastric cancer. Journal of the National Cancer Institute, 101(11), pp. 793-805. (doi:10.1093/jnci/djp103)

Murphy, D.J. , Junttila, M.R., Pouyet, L., Karnezis, A., Shchors, K., Bui, D.A., Brown-Swigart, L., Johnson, L. and Evan, G.I. (2008) Distinct thresholds govern Myc's biological output In vivo. Cancer Cell, 14(6), pp. 447-457. (doi:10.1016/j.ccr.2008.10.018)

Soucek, L., Whitfield, J., Martins, C.P., Finch, A.J., Murphy, D.J. , Sodir, N.M., Karnezis, A.N., Swigart, L.B., Nasi, S. and Evan, G.I. (2008) Modelling Myc inhibition as a cancer therapy. Nature, 455(7213), pp. 679-683. (doi:10.1038/nature07260)

Golipour, A., Myers, D., Seagroves, T., Murphy, D. , Evan, G.I., Donoghue, D.J., Moorehead, R.A. and Porter, L.A. (2008) The Spy1/RINGO family represents a novel mechanism regulating mammary growth and tumorigenesis. Cancer Research, 68(10), pp. 3591-3600. (doi:10.1158/0008-5472.CAN-07-6453)

Rao, M. et al. (2008) Inhibition of cyclin D1 gene transcription by Brg-1. Cell Cycle, 7(5), pp. 647-655. (doi:10.4161/cc.7.5.5446)

Evan, G.I., Christophorou, M., Lawlor, E.A., Ringshausen, I., Prescott, J., Dansen, T., Finch, A., Martins, C. and Murphy, D. (2005) Oncogene-dependent tumor suppression: using the dark side of the force for cancer therapy. Cold Spring Harbor Symposia on Quantitative Biology, 70, pp. 263-273. (doi:10.1101/sqb.2005.70.054)

Flores, I., Murphy, D.J. , Swigart, L.B., Knies, U. and Evan, G.I. (2004) Defining the temporal requirements for Myc in the progression and maintenance of skin neoplasia. Oncogene, 23(35), pp. 5923-5930. (doi:10.1038/sj.onc.1207796)

Murphy, D.J. , Swigart, L.B., Israel, M.A. and Evan, G.I. (2004) Id2 is dispensable for myc-induced epidermal neoplasia. Molecular and Cellular Biology, 24(5), pp. 2083-2090. (doi:10.1128/MCB.24.5.2083-2090.2004)

Deeble, P.D., Murphy, D.J. , Parsons, S.J. and Cox, M.E. (2001) Interleukin-6- and cyclic amp-mediated signaling potentiates neuroendocrine differentiation of lncap prostate tumor cells. Molecular and Cellular Biology, 21(24), pp. 8471-8482. (doi:10.1128/MCB.21.24.8471-8482.2001)

Murphy, D.J. , Hardy, S. and Engel, D.A. (1999) Human SWI-SNF component BRG1 represses transcription of the c-fos gene. Molecular and Cellular Biology, 19(4), pp. 2724-33.

This list was generated on Sun Jul 21 11:18:57 2019 BST.